Nur Nicholson Sells 825 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 825 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total value of $24,354.00. Following the sale, the insider now owns 83,664 shares in the company, valued at $2,469,761.28. The trade was a 0.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Nur Nicholson also recently made the following trade(s):

• On Wednesday, January 22nd, Nur Nicholson sold 3,948 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.43, for a total value of $120,137.64.
• On Friday, January 17th, Nur Nicholson sold 2,145 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total value of $64,264.20.

Apellis Pharmaceuticals Trading Up 3.3 %

NASDAQ:APLS traded up $0.99 during trading hours on Thursday, hitting $30.46. 232,907 shares of the stock were exchanged, compared to its average volume of 1,954,741. The company’s 50 day moving average is $32.20 and its two-hundred day moving average is $32.96. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The company has a market capitalization of $3.79 billion, a P/E ratio of -14.99 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. During the same quarter last year, the company posted ($1.17) EPS. Apellis Pharmaceuticals’s revenue for the quarter was up 78.3% on a year-over-year basis. On average, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Mizuho decreased their price target on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th. Citigroup cut their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Piper Sandler cut their price objective on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. Robert W. Baird cut their price objective on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, Morgan Stanley assumed coverage on Apellis Pharmaceuticals in a research report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price objective for the company. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new stake in shares of Apellis Pharmaceuticals in the second quarter valued at approximately $2,350,000. AQR Capital Management LLC increased its stake in Apellis Pharmaceuticals by 337.3% in the second quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock valued at $9,177,000 after acquiring an additional 190,420 shares during the last quarter. Teachers Retirement System of The State of Kentucky bought a new position in Apellis Pharmaceuticals in the second quarter valued at approximately $725,000. Duncan Williams Asset Management LLC bought a new position in Apellis Pharmaceuticals in the third quarter valued at approximately $609,000. Finally, Handelsbanken Fonder AB increased its stake in Apellis Pharmaceuticals by 15.5% in the third quarter. Handelsbanken Fonder AB now owns 27,600 shares of the company’s stock valued at $796,000 after acquiring an additional 3,700 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).